Quick Answer
Lantern Pharma Inc. reported Net Income of -$17.12 million for fiscal year 2025.
Lantern Pharma Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$17.12M | +17.6% |
| 2024 | -$20.78M | -30.2% |
| 2023 | -$15.96M | -11.9% |
| 2022 | -$14.26M | -15.3% |
| 2021 | -$12.36M | -109.3% |
| 2020 | -$5.91M | -143.3% |
| 2019 | -$2.43M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.18M | +7.3% | +3.5% |
| June 30, 2025 | -$4.33M | +12.7% | +4.5% |
| March 31, 2025 | -$4.54M | +16.6% | -0.7% |
| September 30, 2024 | -$4.51M | -42.5% | +9.2% |
| June 30, 2024 | -$4.96M | -4.5% | +8.8% |
| March 31, 2024 | -$5.44M | -40.7% | -72.1% |
| September 30, 2023 | -$3.16M | -39.6% | +33.4% |
| June 30, 2023 | -$4.75M | -5.7% | -22.7% |
- Lantern Pharma Inc. showed an increase of +17.6% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Lantern Pharma Inc.’s net income has declined by 605.0% (from -$2.43 million to -$17.12 million).
- The most recent figure is from Lantern Pharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: